Cargando…
Comparative Survival of Asian and White Metastatic Castration-Resistant Prostate Cancer Men Treated With Docetaxel
There are few data regarding disparities in overall survival (OS) between Asian and white men with metastatic castration-resistant prostate cancer (mCRPC). We compared OS of Asian and white mCRPC men treated in phase III clinical trials with docetaxel and prednisone (DP) or a DP-containing regimen....
Autores principales: | Halabi, Susan, Dutta, Sandipan, Tangen, Catherine M, Rosenthal, Mark, Petrylak, Daniel P, Thompson, Ian M, Chi, Kim N, De Bono, Johann S, Araujo, John C, Logothetis, Christopher, Eisenberger, Mario A, Quinn, David I, Fizazi, Karim, Morris, Michael J, Higano, Celestia S, Tannock, Ian F, Small, Eric J, Kelly, William Kevin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7190204/ https://www.ncbi.nlm.nih.gov/pubmed/32368717 http://dx.doi.org/10.1093/jncics/pkaa003 |
Ejemplares similares
-
Androgen Decline and Survival During Docetaxel Therapy in metastatic Castration Resistant Prostate Cancer (mCRPC)
por: Ryan, Charles J, et al.
Publicado: (2019) -
Patient-reported outcomes for patients with metastatic castration-resistant prostate cancer receiving docetaxel and Atrasentan versus docetaxel and placebo in a randomized phase III clinical trial (SWOG S0421)
por: Unger, Joseph M., et al.
Publicado: (2018) -
Radium-223 in combination with docetaxel in patients with castration-resistant prostate cancer and bone metastases: a phase 1 dose escalation/randomised phase 2a trial
por: Morris, Michael J., et al.
Publicado: (2019) -
Phase I/II trial of cabazitaxel plus abiraterone in patients with metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel and abiraterone
por: Massard, C., et al.
Publicado: (2017) -
Comparison of Joint and Landmark Modeling for Predicting Cancer Progression in Men With Castration-Resistant Prostate Cancer: A Secondary Post Hoc Analysis of the PREVAIL Randomized Clinical Trial
por: Finelli, Antonio, et al.
Publicado: (2021)